Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit Low Response to Cetuximab

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Ather, Ferdows ^a   Hamidi, Habib ^a   Fejzo, Marlena S ^a   Letrent, Stephen ^b   Finn, Richard S ^a   Kabbinavar, Fairooz ^a   Head, Christian ^a   Wong, Steven G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; DACOMITINIB; ERLOTINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; VASCULOTROPIN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CONTROLLED STUDY; DRUG APPROVAL; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME PHOSPHORYLATION; FOOD AND DRUG ADMINISTRATION; G1 PHASE CELL CYCLE CHECKPOINT; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IC 50; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HEAD AND NECK NEOPLASMS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; QUINAZOLINONES; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84873542842     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056112     Document Type: Article

References (44)

1. Haddad RI, Shin DM, (2008) Recent advances in head and neck cancer. N Engl J Med 359: 1143-1154.
2. Hunter KD, Parkinson EK, Harrison PR, (2005) Profiling early head and neck cancer. Nat Rev Cancer 5: 127-135.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, et al. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182.
4. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634.
5. Garon EB, Finn RS, Hosmer W, Dering J, Ginther C, et al. (2010) Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines. Mol Cancer Ther 9: 1985-1994.
6. Herbst RS, Shin DM, (2002) Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 94: 1593-1611.
7. Hynes NE, Lane HA, (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354.
8. Mendelsohn J, Baselga J, (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21: 2787-2799.
9. Carpenter CL, Duckworth BC, Auger KR, Cohen B, Schaffhausen BS, et al. (1990) Purification and characterization of phosphoinositide 3-kinase from rat liver. J Biol Chem 265: 19704-19711.
10. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, et al. (2006) Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366: 2-16.
11. Demiral AN, Sarioglu S, Birlik B, Sen M, Kinay M, (2004) Prognostic significance of EGF receptor expression in early glottic cancer. Auris Nasus Larynx 31: 417-424.
12. Maurizi M, Almadori G, Ferrandina G, Distefano M, Romanini ME, et al. (1996) Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer 74: 1253-1257.
13. Rubin Grandis J, Melhem MF, Gooding WE, Day R, Holst VA, et al. (1998) Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90: 824-832.
14. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, et al. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21: 2237-2246.
15. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, et al. (2007) Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25: 1545-1552.
16. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, et al. (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567-578.
17. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, et al. (2009) A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27: 672-680.
18. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, et al. (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359: 1116-1127.
19. Britten CD, (2004) Targeting ErbB receptor signaling: a pan-ErbB approach to cancer. Mol Cancer Ther 3: 1335-1342.
20. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, et al. (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355: 2733-2743.
21. Gonzales AJ, Hook KE, Althaus IW, Ellis PA, Trachet E, et al. (2008) Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther 7: 1880-1889.
22. Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, et al. (2007) PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 67: 11924-11932.
23. Kalous O, Conklin D, Desai AJ, O'Brien NA, Ginther C, et al. (2012) Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib. Molecular cancer therapeutics 11: 1978-1987.
24. Janne PA, Boss DS, Camidge DR, Britten CD, Engelman JA, et al. (2011) Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clinical cancer research: an official journal of the American Association for Cancer Research 17: 1131-1139.
25. Janne P, Reckamp K, Koczywas M, Engelman J, Camidge D, et al. (2009) Efficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment wtih erlotinib (E): A two-arm, phase II trial. J Clin Oncol 27: S.
26. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792.
27. Qiu W, Schonleben F, Li X, Ho DJ, Close LG, et al. (2006) PIK3CA mutations in head and neck squamous cell carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research 12: 1441-1446.
28. Lee JW, Soung YH, Kim SY, Nam HK, Park WS, et al. (2005) Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clinical cancer research: an official journal of the American Association for Cancer Research 11: 2879-2882.
29. Wainberg ZA, Anghel A, Desai AJ, Ayala R, Luo T, et al. (2010) Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res 16: 1509-1519.
30. Leonard JH, Kearsley JH, Chenevix-Trench G, Hayward NK, (1991) Analysis of gene amplification in head-and-neck squamous-cell carcinoma. Int J Cancer 48: 511-515.
31. Huang F, Goh LK, Sorkin A, (2007) EGF receptor ubiquitination is not necessary for its internalization. Proc Natl Acad Sci U S A 104: 16904-16909.
32. Butowski N, Chang SM, (2005) Small molecule and monoclonal antibody therapies in neurooncology. Cancer control: journal of the Moffitt Cancer Center 12: 116-124.
33. Dancey J, Sausville EA, (2003) Issues and progress with protein kinase inhibitors for cancer treatment. Nature reviews Drug discovery 2: 296-313.
34. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, et al. (2005) Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer cell 7: 301-311.
35. Ward WH, Cook PN, Slater AM, Davies DH, Holdgate GA, et al. (1994) Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochemical pharmacology 48: 659-666.
36. Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, et al. (1997) Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer research 57: 4838-4848.
37. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, et al. (2006) Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer research 66: 1630-1639.
38. Lammering G, Hewit TH, Valerie K, Contessa JN, Amorino GP, et al. (2003) EGFRvIII-mediated radioresistance through a strong cytoprotective response. Oncogene 22: 5545-5553.
39. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, et al. (1992) Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proceedings of the National Academy of Sciences of the United States of America 89: 2965-2969.
40. Morris JPt, Wang SC, Hebrok M, (2010) KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer 10: 683-695.
41. Brenner JC, Graham MP, Kumar B, Saunders LM, Kupfer R, et al. (2010) Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines. Head & neck 32: 417-426.
42. Uphoff CC, Drexler HG, (2002) Detection of mycoplasma in leukemia-lymphoma cell lines using polymerase chain reaction. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 16: 289-293.
43. Ginther C, Issel-Tarver L, King MC, (1992) Identifying individuals by sequencing mitochondrial DNA from teeth. Nature genetics 2: 135-138.
44. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, et al. (2009) PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast cancer research: BCR 11: R77.